SOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call Transcript
SOPHiA GENETICS (NASDAQ:SOPH) & Hims & Hers Health (NYSE:HIMS) Financial Comparison
Hims and Hers Health (NYSE: HIMS - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Valuation and Earnings This table compares
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q3 2025 Earnings Call Transcript
SOPHiA GENETICS SA ( SOPH ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder, CEO & Director Ross Muken - President George Cardoza - Executive VP & CFO Conference Call Participants William Bonello - Craig-Hallum Capital Group LLC, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Kyle Boucher - TD Cowen, Research Division Presentation Operator Good morning. My name is Kelsey, and I'll be your conference operator today.
SOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call Transcript
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants George A. Cardoza - Executive VP & CFO Jurgi Camblong - Co-Founder, CEO & Director Kellen Sanger - Head of Strategy and Investor Relations Ross Jordan Muken - President Conference Call Participants Conor Noel McNamara - RBC Capital Markets, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Subhalaxmi T.
SOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call Transcript
SOPHiA GENETICS SA. (NASDAQ:SOPH ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Conor McNamara - RBC Capital Markets Subbu Nambi - Guggenheim Operator Good morning, ladies and gentlemen, and welcome to the SOPHiA GENETICS Q1 2025 Earnings Call.
SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock?
SOPHiA GENETICS (SOPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SOPHiA GENETICS SA (SOPH) Q4 2024 Earnings Call Transcript
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q4 2024 Earnings Call March 4, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Mark Massaro - BTIG Tejas Savant - Morgan Stanley Bill Bonello - Craig-Hallum Operator Good morning. My name is Liway and I'll be your conference operator today.
SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates
SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.37 per share a year ago.
SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer George Cardoza - Incoming Chief Financial Officer Ross Muken - Executive Vice President, Chief Financial Officer & Chief Operating Officer Conference Call Participants Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Conor McNamara - RBC Capital Markets Operator Good morning. My name is Nicole [ph] and I will be your conference operator today.
SOPHiA GENETICS (SOPH) Loses -30.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for SOPHiA GENETICS (SOPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
What Makes SOPHiA GENETICS (SOPH) a New Buy Stock
SOPHiA GENETICS (SOPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
